Ignite Creation Date:
2025-12-24 @ 11:52 PM
Ignite Modification Date:
2026-01-13 @ 7:45 AM
Study NCT ID:
NCT05228951
Status:
RECRUITING
Last Update Posted:
2022-09-13
First Post:
2022-01-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
Sponsor:
Shengjing Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-02-10
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-13
First Submit QC Date:
None
Study First Post Date:
2022-02-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-09-12
Last Update Post Date:
2022-09-13
Last Update Post Date Type:
ACTUAL